Zealand Pharma announces promising results from dapiglutide trial for obesity treatment
Zealand Pharma A/S (Nasdaq: ZEAL), a pioneer in peptide-based drug development, has shared topline results from its DREAM trial, evaluating the efficacy of low doses of the GLP-1/GLP-2 receptor dual agonist, dapiglutide, in treating obesity. This clinical study marks a significant step forward in understanding the potential of dapiglutide to induce weight loss without lifestyle […]